Market Research Report
Europe Cephalosporin Drugs Market (2019-2025)
|Published by||KBV Research||Product code||906240|
|Published||Content info||118 Pages
Delivery time: 1-2 business days
|Europe Cephalosporin Drugs Market (2019-2025)|
|Published: July 31, 2019||Content info: 118 Pages||
The Europe Cephalosporin Drugs Market would witness market growth of 2.94% CAGR during the forecast period (2019-2025).
Cephalosporin Drugs is a bactericidal, wide-spectrum, B-lactam antibiotic initially extracted from the Acremonium fungus that is used to treat bacterial diseases such as pneumonia, skin diseases, tonsillitis, otitis media, bronchitis, gonorrhea, and others. It is similar to penicillin and is, therefore, used as an option to penicillin-allergic patients.
Developing extremely effective and secure Cephalosporin Drugs, growing mergers and corporate acquisitions to manufacturing these drugs are likely to create growth opportunities for the market for Cephalosporin Drugs in the coming years. On the other hand, low R&D investment and rigid public policies on these medicines hamper the market growth.
Based on Generation, the market is segmented into First-Generation Cephalosporin, Second-Generation Cephalosporin, Third-Generation Cephalosporin, Fourth-Generation Cephalosporin, and Fifth-Generation Cephalosporin. Based on Application, the market is segmented into Respiratory Tract Infection, Skin Infection, Ear Infection, Sexually Transmitted Infection and Others. Based on Route of Administration, the market is segmented into Injections and Oral Drugs. Based on Type, the market is segmented into Branded and Generic. Based on countries, the market is segmented into Germany, UK, France, Russia, Spain, Italy, and Rest of Europe.
The market research report covers the analysis of key stake holders of the market. Key companies profiled in the report ABBOTT Laboratories, Teva Pharmaceuticals Industries Ltd., Johnson and Johnson, GlaxoSmithKline PLC (GSK), Pfizer, Inc., Merck & Co., Inc., Bayer AG, Baxter International, Inc., Bristol-Myers Squibb Company and Novartis AG.